Comparable Survival Outcomes and Reduced Risk of Low-Dose Whole-ventricle Radiation Therapy with Chemotherapy in Central Nervous System Germinomas
Neuro-Oncology Pediatrics · 11.07.2026
DOI: 10.1093/neuped/wuag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, online erschienen am 11.07.2026. Verfasst von Etsuko Yamamoto Hattori und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The optimal radiation dose and boost volume for central nervous system (CNS) germinomas remain unestablished. Although radiotherapy is crucial for long-term prognosis, its late adverse effects are an increasing concern. While reducing radiation doses and field sizes has been advocated, the reduction of late toxicities remains unclear.
Methods
Outcomes and adverse effect rates of CNS germinomas treated at Kyoto University Hospital from 1981 to 2021 were retrospectively analyzed.
Results
Fifty-five patients were categorized by treatment: high-dose (≥50 Gy) whole-brain radiotherapy without chemotherapy (WB-HD; n = 4), low-dose (24.0-45.6 Gy) whole-brain radiotherapy without chemotherapy (WB-LD; n = 10), 20.4-25.2 Gy whole-brain radiotherapy with chemotherapy (WB-LD+CT; n = 7), and 20.4-39.6 Gy whole-ventricle radiotherapy with chemotherapy (WV+CT; n = 34). No significant difference in progression-free survival (PFS) was observed among these subgroups and the WB-HD group (P = .835). Compared with WB-LD+CT, WV+CT involving a lower radiation dose was associated with a significantly lower incidence of anterior hypopituitarism (P < .001). Regarding late toxicities, seven of eight patients who developed microbleeds received a local boost plus baseline irradiation (WB or WV), with a mean perilesional dose of 45.1 Gy. Conversely, no patients without microbleeds received boost irradiation; all were treated with baseline irradiation alone, receiving a significantly lower mean dose of 23.9 Gy (P < .001).
Conclusions
Low-dose (approximately 23.4-24 Gy) WV+CT achieved PFS outcomes comparable to WB-HD. WV+CT significantly reduced anterior hypopituitarism, and omitting boost irradiation reduced microbleed incidence, supporting low-dose WV+CT without boost as a feasible treatment strategy for CNS germinomas.
Zitieren
APA
Hattori, E. Y., Mineharu, Y., Umeda, K., Takada, S., Sano, N., Tanji, M., Uto, M., Furukawa, K., Takita, J., Mizowaki, T., & Arakawa, Y. (2026). Comparable Survival Outcomes and Reduced Risk of Low-Dose Whole-ventricle Radiation Therapy with Chemotherapy in Central Nervous System Germinomas. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuag040
Vancouver
Hattori EY, Mineharu Y, Umeda K, Takada S, Sano N, Tanji M, et al. Comparable Survival Outcomes and Reduced Risk of Low-Dose Whole-ventricle Radiation Therapy with Chemotherapy in Central Nervous System Germinomas. Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuag040
BibTeX
@article{Hattori2026,
author = {Hattori, Etsuko Yamamoto and Mineharu, Yohei and Umeda, Katsutsugu and Takada, Shigeki and Sano, Noritaka and Tanji, Masahiro and Uto, Megumi and Furukawa, Keiko and Takita, Junko and Mizowaki, Takashi and Arakawa, Yoshiki},
title = {Comparable Survival Outcomes and Reduced Risk of Low-Dose Whole-ventricle Radiation Therapy with Chemotherapy in Central Nervous System Germinomas},
journal = {Neuro-Oncology Pediatrics},
year = {2026},
doi = {10.1093/neuped/wuag040}
}
EUVIMED